Conexeu Sciences Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Conexeu Sciences Inc. engages in the development and commercialization of regenerative biomaterials and tissue engineering solutions primarily for wound care, aesthetics, and soft tissue reconstruction. The company focuses on collagen-based technologies built around its CXU Scaffold Platform, a temperature-sensitive extracellular matrix scaffold that transitions to a gel-like state in vivo to support cell growth, tissue integration, and accelerated healing. Its flagship product developments include regenerative biomaterial solutions intended for skin regeneration, wound closure, and soft tissue augmentation, with applications spanning diabetic ulcers, acute and chronic wounds, dermal fillers, and aesthetic medicine indications. Headquartered in Paris, Île-de-France, France, Conexeu Sciences Inc. operates within the medical technology and regenerative medicine sectors, pursuing partnerships and collaborations to advance device-based therapies from research to pre-commercial and early-commercial stages. The company traces its origins to cellular therapy and regenerative medicine research programs and emphasizes a pathway through regulatory engagement and staged product development toward market entry. Its strategy centers on enabling physicians with scaffold-assisted tissue regeneration products designed to improve healing outcomes and reduce recovery times in both clinical and aesthetic settings. Latest major company changes include strategic partnerships and collaborations to advance CXU Scaffold technology through joint development and potential co-commercialization agreements; participation in regulatory discussions and designations as it progresses its device candidate through pre-market processes; and ongoing funding rounds and convertible securities transactions to support manufacturing process development, supplier qualification, regulatory strategy, and documentation rigor. The company has announced or engaged in initiatives related to expanding its commercial development program, including manufacturing process development and regulatory planning, in addition to pursuing strategic investments and equity offerings to support its growth trajectory. Industry positioning centers on regenerative medicine, wound care, aesthetics, and soft tissue reconstruction, with target markets comprising clinicians and patients requiring advanced wound therapies and cosmetic tissue restoration. The company’s product and service suite includes CXU Scaffold technology, scaffold-based regenerative therapies, liquid or gel-forming tissue substitutes, and related device development activities for skin regeneration and wound healing. Conexeu maintains an international footprint through development activities and potential commercial operations, with its core activities anchored in research, regulatory strategy, and early-stage manufacturing development to bring innovative regenerative solutions to the market.
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"